Taylor Kantor
@taylorkantor
Lucky Husband, Father of two, patient advocate. Co-Founder and Chief Medical Officer, Ivim Health
You might like
New research on mazdutide, a GLP-1/glucagon dual agonist, shows adults with overweight or obesity lost up to 22% of their body weight over 48 weeks. Dual-action therapies are expanding options for metabolic care. #GLP1 healio.com/news/endocrino…
Real-world data: Ozempic & Mounjaro cut major cardiovascular events by up to ~18% in type 2 diabetes patients. Access matters. But optimizing care is the next frontier. #GLP1 #MetabolicHealth sciencedaily.com/releases/2025/…
Lower GLP-1 prices for cash-pay patients are a major step toward early access and prevention. The challenge now is turning that access into lasting health by building the long-term support and care systems patients need. #GLP1 nbcnews.com/health/health-…
The mass-market moment for GLP-1s is here. Progress means pairing access with education, prevention, and real lifestyle change. #GLP1 wsj.com/health/pharma/…
Tirzepatide may offer heart-protective benefits beyond weight loss, building on what we know from semaglutide. Prevention starts before complications appear. #GLP1 massgeneralbrigham.org/en/about/newsr…
Falling GLP-1 prices expand access; now prevention must lead. Medication works best when paired with lifestyle and long-term care. #GLP1 wsj.com/opinion/weight…
Coverage expansion for GLP-1s could be a milestone in obesity care. But access alone isn’t enough. Lasting health requires a system that treats prevention with urgency. #GLP1 usatoday.com/story/money/20…
Oral GLP-1s showing heart protection similar to injectables is real progress. Simpler access means stronger prevention. #GLP1 #HeartHealth reuters.com/business/healt…
“I wish someone told me this earlier.” I hear it all the time. GLP-1s are powerful, but most effective when paired with lifestyle change. The best outcomes happen when science meets daily habits. #GLP1 medicalxpress.com/news/2025-10-h…
FDA approved oral semaglutide for CV risk reduction in high-risk T2D — a practical win for prevention. Pair it with earlier access and integrated care, and we avoid more invasive care down the line. #GLP1 medpagetoday.com/cardiology/gen…
U.S. obesity rates are finally declining. Not a miracle — medicine working on the biology. Now the work is ensuring outcomes mean more than a number. #GLP1 usatoday.com/story/life/hea…
New Medscape data: GLP-1s are associated with lower heart and mortality risk in psoriatic arthritis. Metabolism, inflammation, and cardiac risk are deeply connected — preventive, integrated care is the future. #GLP1 medscape.com/viewarticle/gl…
New data: metabolic surgery still outperforms GLP-1s on long-term cost. The problem isn’t the tools — it’s how late we use them. Prevention > repair. #GLP1 #MetabolicHealth medscape.com/viewarticle/gl…
GLP-1s continue to show reduced heart attack and stroke risk. Prevention beats intervention every time. #GLP1 medpagetoday.com/primarycare/ob…
New research suggests some GLP-1s could lower heart attack risk even without major weight loss. Tackling metabolic inflammation early may be key to preventing cardiac events before they reach the OR. #CardiometabolicHealth #PreventiveCare #GLP1 theguardian.com/science/2025/o…
That’s a wrap on #HLTH2025. Big momentum around prevention, AI, and new care models — now it’s time to turn ideas into traction.
At @HLTHEVENT, #HLTHUSA 2025, the real innovation isn’t new tech, it’s rethinking care itself. Let’s build a system that keeps people healthy, not just treats them sick. Prevention is the new prescription. #HealthcareInnovation #Prevention #PatientFirst
GLP-1s don’t just help with weight loss; they protect the heart. Prevention and proactive care should be the standard, not the exception. #HeartHealth #MetabolicCare healthline.com/health-news/gl…
When outcomes are comparable, access and affordability matter more than ever. GLP-1s are helping make preventive, whole-person care a reality for more patients. #GLP1 #PreventiveCare medscape.com/viewarticle/si…
New research shows semaglutide’s impact on liver health in MASH may be measurable through noninvasive tests — a safer, smarter step toward precision metabolic care. #GLP1 #MASH #ClinicalCare #MetabolicHealth medscape.com/viewarticle/no…
United States Trends
- 1. Good Sunday 65.1K posts
- 2. Klay 28.1K posts
- 3. #sundayvibes 5,189 posts
- 4. McLaren 119K posts
- 5. Blessed Sunday 17.6K posts
- 6. #FelizCumpleañosNico 4,302 posts
- 7. #FG3Dライブ 110K posts
- 8. #sundaymotivation 3,450 posts
- 9. Ja Morant 13K posts
- 10. #FelizCumpleañosPresidente 3,773 posts
- 11. For the Lord 30.6K posts
- 12. Lando 143K posts
- 13. Tottenham 47.2K posts
- 14. King of the Universe 2,105 posts
- 15. Piastri 85.9K posts
- 16. South Asia 40.5K posts
- 17. Christ the King 10.6K posts
- 18. Rubio 99.5K posts
- 19. Arsenal 175K posts
- 20. Chattanooga State 1,121 posts
Something went wrong.
Something went wrong.